Abstract 3075
Background
Patients are living longer with recurrent breast cancer, yet there is a lack of survivorship programs for these individuals. They face unique challenges due to the lack of curative treatments and limited supportive care resources. Challenges include fluctuations in functional status, changes in relationships, communication with loved ones, and existential concerns. Health related quality of life has been found to be different, further widening the gap in care.
Methods
Survivors were referred for a one-hour coaching intervention tailored to their needs based upon results of their Functional Assessment of Cancer Therapy-Breast (FACT-B) survey. Patient satisfaction was assessed immediately after and at two weeks post the intervention. A paired t-test was used to evaluate quality of life sores before and two weeks following participation in the survivorship session.
Results
Statistically significant (p=.000) improvements were observed overall and in each subscale of the FACT-B survey. Patient satisfaction was high immediately post the intervention and remained high at the two-week assessment.
Conclusions
This project successfully demonstrated that an individual coaching intervention can be implemented to improve the quality of life in patients with recurrent breast cancer. The key findings support that integration of a survivorship program is associated with high patient satisfaction and increased quality of life. As chronic breast cancer survivors encompass a broad and heterogeneous population, survivorship programs should be developed that address the needs of this unique patient population. Creation of an infrastructure that promotes individualized care to survivors with recurrent breast cancer is an essential component of providing holistic care across the cancer continuum. Oncology nurse navigators have a unique relationship with their patients and implementing this program provides an opportunity to address these important and clinically relevant unmet needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Graduate scholarship in Cancer Nursing Practice GSCNP-18-07501 from the American Cancer Society and a Clinical Doctoral Scholarship from the Oncology Nursing Foundation Endowment.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3489 - Overall Survival (OS) and Metastasis-Free Survival (MFS) in men with Biochemically Relapsed (BCR) Prostate Cancer after radical prostatectomy (RP) managed with deferred Androgen Deprivation Treatment (ADT): A combined Johns Hopkins and CPDR study
Presenter: Catherine Marshall
Session: Poster Display session 3
Resources:
Abstract
4606 - ARCHES – the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Presenter: Arnulf Stenzl
Session: Poster Display session 3
Resources:
Abstract
2975 - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study).
Presenter: Orazio Caffo
Session: Poster Display session 3
Resources:
Abstract
2708 - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
Presenter: Alicia Morgans
Session: Poster Display session 3
Resources:
Abstract
2134 - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial
Presenter: Janet Brown
Session: Poster Display session 3
Resources:
Abstract
3504 - Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents – a meta-analysis of randomized controlled trials.
Presenter: Rodrigo Coutinho Mariano
Session: Poster Display session 3
Resources:
Abstract
2342 - Pain progression at initiation of chemotherapy in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA
Presenter: Nicolas Delanoy
Session: Poster Display session 3
Resources:
Abstract
5331 - Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Presenter: Holger Palmedo
Session: Poster Display session 3
Resources:
Abstract
2823 - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
1500 - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
Presenter: Harriet Mintz
Session: Poster Display session 3
Resources:
Abstract